Peter B. Berger
Research Subjects
Peter B. Berger has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Adnan Kastrati
DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance , Munich , Germany 3 Deutsches Herzzentrum München , Technische Universität München , Munich , Germany 4 I. Medizinische Klinik, Klinikum rechts der Isar , Technische Universität München , Munich , Germany
1 shared publicationAlfred S. Casale
Department of Cardiothoracic Surgery, Geisinger Medical Center, Danville, Pennsylvania
1 shared publicationCharles Benoit
Department of Cardiothoracic Surgery, Geisinger Medical Center, Danville, Pennsylvania
1 shared publicationDirk Sibbing
Department of Cardiology , Ludwig-Maximilians-Universität München , Munich , Germany 2 DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance , Munich , Germany
1 shared publicationEdward Woods
Department of Cardiothoracic Surgery, Geisinger Medical Center, Danville, Pennsylvania
1 shared publicationEric S. Wagner
Cardiovascular Center for Clinical Research, Geisinger Medical Center, Danville, Pennsylvania
1 shared publication
Latest Publications
- 1 March 2017
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 10 (5) , 448-450
STEMI Care in Poland and the United States
- 1 March 2017
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 10 (5) , 448-450
STEMI Care in Poland and the United States
- Open Access
- 27 December 2015
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 37 (16) , 1284-1295
Pre-treatment with P2Y12inhibitors in ACS patients: who, when, why, and which agent?
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the mainstay of treatment for acute coronary syndrome (ACS) patients, whether they undergo a percutaneous coronary intervention (PCI) or are managed medically. In recent years, the most appropriate timing for initiation and duration of P2Y12 receptor inhibition has been a focus of great interest. Many observational studies and a single prospective trial (CREDO) utilizing clopidogrel had focused on whether pre-treatment with clopidogrel, i.e. its administration upstream of coronary angiography and PCI, is beneficial. Although the rationale for pre-treatment is obvious, large-scale randomized trials supporting a pre-treatment strategy with clopidogrel or with the newer P2Y12 inhibitors prasugrel and ticagrelor did not exist. Proponents of a pre-treatment strategy had to rely on their best guess, on non-randomized studies, or on negative studies in which a trend for a benefit had been demonstrated. Recently, however, two randomized trials directly evaluated the value of pre-treatment—one in patients with a non-STE elevation myocardial infarction (NSTEMI)—the Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention or as Pretreatment at the Time of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction (ACCOAST) trial, and a second trial evaluating the use of ticagrelor in ST-elevation myocardial infarction (STEMI) patients, the Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST-elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial. Neither of the two trials, however, answered all the questions clinicians have about pre-treatment. And given the recent approval of the intravenous and rapidly acting P2Y12 inhibitor cangrelor, the choice of who should receive treatment with a P2Y12 inhibitor, which one should be used, and when it should be administered, should be carefully re-evaluated for all patients. This clinical review aims at evaluating the available evidence regarding the value of pre-treatment with the now four available oral and intravenous P2Y12 inhibitors that can be administered to patients in whom coronary angiography followed by a possible PCI is planned.
- 27 December 2015
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 37 (16) , 1284-1295
Open AccessPre-treatment with P2Y12inhibitors in ACS patients: who, when, why, and which agent?
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the mainstay of treatment for acute coronary syndrome (ACS) patients, whether they undergo a percutaneous coronary intervention (PCI) or are managed medically. In recent years, the most appropriate timing for initiation and duration of P2Y12 receptor inhibition has been a focus of great interest. Many observational studies and a single prospective trial (CREDO) utilizing clopidogrel had focused on whether pre-treatment with clopidogrel, i.e. its administration upstream of coronary angiography and PCI, is beneficial. Although the rationale for pre-treatment is obvious, large-scale randomized trials supporting a pre-treatment strategy with clopidogrel or with the newer P2Y12 inhibitors prasugrel and ticagrelor did not exist. Proponents of a pre-treatment strategy had to rely on their best guess, on non-randomized studies, or on negative studies in which a trend for a benefit had been demonstrated. Recently, however, two randomized trials directly evaluated the value of pre-treatment—one in patients with a non-STE elevation myocardial infarction (NSTEMI)—the Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention or as Pretreatment at the Time of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction (ACCOAST) trial, and a second trial evaluating the use of ticagrelor in ST-elevation myocardial infarction (STEMI) patients, the Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST-elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial. Neither of the two trials, however, answered all the questions clinicians have about pre-treatment. And given the recent approval of the intravenous and rapidly acting P2Y12 inhibitor cangrelor, the choice of who should receive treatment with a P2Y12 inhibitor, which one should be used, and when it should be administered, should be carefully re-evaluated for all patients. This clinical review aims at evaluating the available evidence regarding the value of pre-treatment with the now four available oral and intravenous P2Y12 inhibitors that can be administered to patients in whom coronary angiography followed by a possible PCI is planned.
- Open Access
- 20 May 2015
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 28 (3) , 223-232
Does Preoperative Platelet Function Predict Bleeding in Patients Undergoing Off Pump Coronary Artery Bypass Surgery?
Objective: We sought to examine the relationship between preoperative platelet function and perioperative bleeding in patients undergoing CABG.Background: There are many ways to measure platelet aggregability. Little is known about their correlations with one another, or with bleeding.Methods: We prospectively studied 50 patients undergoing a first isolated off‐pump CABG. Thirty‐four were exposed to a thienopyridine prior to surgery; 16 were not. Preoperative platelet function was measured by VerifyNow®, TEG®, AggreGuide™, Plateletworks®, vasodilator‐stimulated phosphoprotein (VASP) phosphorylation, and light transmission aggregometry. Bleeding was assessed 2 ways: drop from pre‐ to nadir postoperative hematocrit, and chest tube drainage. Correlation coefficients were calculated using Spearman's rank‐order correlation.Results: Mean age was 62 years. Patient characteristics and surgical details were similar between the thienopyridine‐exposed and non‐exposed patients. The correlation coefficients between the 4 point‐of‐care platelet function measurements and hematocrit change ranged from −0.2274 to 0.2882. Only Plateletworks® correlated with drop in hematocrit (r = 0.2882, P = 0.0470). The correlation coefficients between each of the 4 point‐of‐care platelet function tests and the chest tube drainage were also poor, ranging from −0.3073 to 0.2272. Both AggreGuide™ (r = −0.3073, P = 0.0317) and VASP (r = −0.3187, P = 0.0272) were weakly but significantly correlated with chest tube drainage. The correlation among the 4 point‐of‐care platelet function measurements was poor, with coefficients ranging from −0.2504 to 0.1968.Conclusions: We observed little correlation among 4 platelet function tests, and between those assays and perioperative bleeding defined 2 different ways. Whether any of these assays should be used to guide decision making in individual patients is unclear. (J Interven Cardiol 2015;28:223–232)
- 20 May 2015
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 28 (3) , 223-232
Open AccessDoes Preoperative Platelet Function Predict Bleeding in Patients Undergoing Off Pump Coronary Artery Bypass Surgery?
Objective: We sought to examine the relationship between preoperative platelet function and perioperative bleeding in patients undergoing CABG.Background: There are many ways to measure platelet aggregability. Little is known about their correlations with one another, or with bleeding.Methods: We prospectively studied 50 patients undergoing a first isolated off‐pump CABG. Thirty‐four were exposed to a thienopyridine prior to surgery; 16 were not. Preoperative platelet function was measured by VerifyNow®, TEG®, AggreGuide™, Plateletworks®, vasodilator‐stimulated phosphoprotein (VASP) phosphorylation, and light transmission aggregometry. Bleeding was assessed 2 ways: drop from pre‐ to nadir postoperative hematocrit, and chest tube drainage. Correlation coefficients were calculated using Spearman's rank‐order correlation.Results: Mean age was 62 years. Patient characteristics and surgical details were similar between the thienopyridine‐exposed and non‐exposed patients. The correlation coefficients between the 4 point‐of‐care platelet function measurements and hematocrit change ranged from −0.2274 to 0.2882. Only Plateletworks® correlated with drop in hematocrit (r = 0.2882, P = 0.0470). The correlation coefficients between each of the 4 point‐of‐care platelet function tests and the chest tube drainage were also poor, ranging from −0.3073 to 0.2272. Both AggreGuide™ (r = −0.3073, P = 0.0317) and VASP (r = −0.3187, P = 0.0272) were weakly but significantly correlated with chest tube drainage. The correlation among the 4 point‐of‐care platelet function measurements was poor, with coefficients ranging from −0.2504 to 0.1968.Conclusions: We observed little correlation among 4 platelet function tests, and between those assays and perioperative bleeding defined 2 different ways. Whether any of these assays should be used to guide decision making in individual patients is unclear. (J Interven Cardiol 2015;28:223–232)